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(57) ABSTRACT 
Multimodal nanoparticles are nanoparticles containing con-
trast agents for PAT and one or more ofluminescence imag-
ing, x-ray imaging, and/or MRI. The multimodal nanopar-
ticles can have a dielectric core comprising an oxide with a 
metal coating on the core. The particles can be metal speck-
led. The multimodal nanoparticles can be used for therapeutic 
purposes such as ablation of tumors or by neutron capture in 
addition to use as contrast agents for imaging. 
6 Claims, 13 Drawing Sheets 
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MULTIMODAL NANOPARTICLES FOR 
NON-INVASIVE BIO-IMAGING 
CROSS-REFERENCE TO RELATED 
APPLICATION 
2 
oxide, for example silicon dioxide, with a metal, for example 
gold, deposited on the dielectric core. The multimodal nano-
particle also has a plurality of at least one moiety that exhibits 
luminescence, magnetic or paramagnetic properties, x-ray 
opacity, or any combination of these properties. A single 
moiety can act as one or more contrast agents for photo 
acoustic tomography (PAT) imaging, luminescence imaging, 
magnetic resonance (MR) imaging, and x-ray imaging. The 
multimodal nanoparticle can have multiple moieties which 
This application is the U.S. national stage application of 
International Patent Application No. PCT/US2008/074630, 
filed Aug. 28, 2008, which claims the benefit of U.S. Provi-
sional Patent Application No. 60/968,476, filed Aug. 28, 
2007, the disclosures of which are hereby incorporated by 
reference in their entireties, including all figures, tables or 
drawings. 
10 behave as different contrast agents for different imaging tech-
niques. For example, in one embodiment a luminescence 
imaging moiety can be a dye, a quantum dot, a phosphor or a 
combination thereof. In another embodiment an MR imaging 
moiety can be at least one chelated lanthanide or transition 
BACKGROUND OF THE INVENTION 15 metal. 
In one embodiment of the invention the multimodal nano-
particle is a metal speckled particle, for example gold speck-
led silicate (GSS) nanoparticle. The metal deposition is 
speckled where a discontinuous metal and dielectric core 
20 have a non-discrete interface with an interpenetrated gradi-
ent. In an embodiment of the invention, the multimodal nano-
particles can also have a biomolecule or a surface functional 
group attached to its surface by any means such that the 
biomolecule or functional group allow specific targeting of a 
Bio-imaging techniques can non-invasively measure bio-
logical functions, evaluate cellular and molecular events, and 
reveal the inner workings of a body. Examples ofbio-imaging 
techniques include magnetic resonance imaging (MRI), 
positron emission tomography (PET), x-ray tomography, 
luminescence (optical imaging), and ultrasound. Each of 
these techniques can differ from one another in the resolution, 
sensitivity, and anatomical information they provide about 
the subject. For example, though optical imaging has high 
sensitivity, it provides limited anatomical background infor-
mation, and can display artifacts due to tissue absorbance and 
scattering. Photo acoustic tomography (PAT), an emerging 
non-invasive imaging modality, uses a non-ionizing optical 
(pulsed laser) source to generate contrast, which is detected as 30 
an acoustic signal whose scattering is 2-3 orders of magnitude 
weaker than optical scattering in biological tissues, the pri-
mary limitation of optical imaging. MRI on the other hand 
can be used to generate contrast to detect tumors in deep 
tissue and provide true three dimensional imaging ofbiologi- 35 
cal structures and processes at cellular resolution. X-ray con-
trast is useful to differentiate tissues with small differences in 
their opacity. 
25 tumor cell. 
It is often necessary to use more than one imaging tech-
nique to integrate the strengths of each while overcoming the 40 
limitations of the individual techniques to improve diagnos-
tics, preclinical research and therapeutic monitoring. How-
ever, each of these techniques typically uses a different con-
trast agent, so using more than one bio-imaging technique 
requires additional time, expense and can complicate the 45 
diagnostic process. It would be desirable to have a multimo-
dal contrast agent that can be used for more than one bio-
imaging technique. Multi-modal contrast agents for bioim-
aging can also serve as important tools for developing and 
benchmarking experimental imaging technologies by using 50 
parallel experiments with mature, proven technologies. The 
application of multimodal contrast agents is particularly 
important for developing less expensive, more available, and 
reliable bio-imaging technologies, such as PAT, that have the 
potential to make advanced medical diagnostics available to 55 
impoverished populations, as well as more commonplace 
worldwide. Although imaging technologies such as CT and 
MRI have become prevalent, the related capital costs associ-
ated with obtaining and maintaining existing equipment 
financially limits its widespread application, even in modern 60 
societies. 
BRIEF SUMMARY OF THE INVENTION 
Another embodiment of the invention is directed to a 
method for multimodal bio-imaging where a multimodal 
nanoparticle, as described above, is introduced to a desired 
location, which is then imaged by photo acoustic tomography 
(PAT) and at least one other imaging method selected from 
magnetic resonance, luminescence, and x-rays imaging. The 
multimodal nanoparticles enhance the contrast observed in 
the resulting images. The different modes of imaging can be 
simultaneously or sequentially performed. 
Another embodiment of the invention is directed to a 
method for using multimodal nanoparticles, as described 
above, for therapeutic purposes where a multimodal nanopar-
ticle is delivered to a desired target region, such as tissue 
containing tumors. The multimodal nanoparticle can then be 
irradiated with electromagnetic radiation which generates 
heat when the multimodal nanoparticles absorb radiation. 
Sufficient electromagnetic radiation can be provided to cause 
local heating that is sufficiently high to kill tumor cells that 
have the multimodal nanoparticles on or contained within the 
tumor. Electromagnetic radiation can be from any region of 
the spectrum including, but not limited to infrared, near infra-
red, visible, near ultraviolet and ultraviolet. In another 
embodiment of the invention, irradiation of the multimodal 
nanoparticles for therapeutic purposes can be neutron irradia-
tion, such that the multimodal nanoparticles emit x-rays, 
gamma rays or Auger electrons, which destroy cells in the 
vicinity of the multipurpose nanoparticles. 
Another embodiment of the invention is a method for pre-
paring multimodal nanoparticles as described above by form-
ing a core of primarily a dielectric material, depositing a 
metal on the core, and attaching at least one moiety that 
exhibits luminescence, magnetic or paramagnetic properties, 
x-ray opacity, to the core or the metal. The core can be formed 
by condensation of a metal oxide precursor in a water-in-oil 
microemulsion. The metal can be deposited by reduction of a 
dissolved metal salt in the presence of a reducing agent. One 
moiety that can be attached to the nanoparticle is a chelated 
lanthanide or transition metal where a ligand bound alkox-
ysilane chelated to a metal is condensed with the metal oxide 
In an embodiments of the invention, a multimodal nano-
particle, for use as a contrast agent for PAT and at least one 
other imaging method, has a dielectric core of at least one 
65 precursor during formation of the core or by condensation of 
the alkoxysilane with a residue from the precursor after for-
mation of the core. Some moieties, such as luminescence 
US 8,361,437 B2 
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providing dyes or phosphors or quantum dots, can be admix-
ing with the metal oxide precursors and be bound or 
entrapped within the core upon condensation. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 schematically depicts a multimodal nanoparticle 
according to an embodiment of the invention. 
4 
with TR=500 ms; and Panel IV is the T 2 weighted spin-echo 
image with TR =500 ms, TE= 100 ms according to an embodi-
ment of the invention. 
FIGS. lSA-B show representative (FIG. lSA) SEM and 
5 (FIG. lSB) TEM images of multimodal nanoparticles accord-
ing to the invention. 
FIG. 2 shows a schematic of passive targeting of tumor 
cells by multimodal nanoparticles promoted by enhanced 10 
permeability and retention according to an embodiment of the 
FIG. 16 shows x-ray contrast from the multimodal nano-
particles (A and B) showing strong contrast to that of water 
(C) according to an embodiment of the invention. 
FIGS. 17A-D show in-vivo MR images of multimodal 
nanoparticle labeled 174 cells in mouse leg where: FIG. 17A 
is spin echo (Msme) TR=l s, TE=30 ms, matrix=256x256, 
FOV=2.8x2.74 cm, 2 avg, 1 mm slice; FIG. 17B gradient 
echo (FLASH) TR=500 ms, TE=4 ms, matrix=256x256, 
invention. 
FIG. 3 shows a photo acoustic tomography PAT image of 
gold speckled silica nanoparticles (GSS) and for a silica par-
ticle according to an embodiment of the invention. 
FIG. 4A shows a T1 weighted magnetic resonance (MR) 
image of a silica particle and that of a Gd-doped GSS sample 
and FIG. 4B shows a T 2 weighted T 1 weighted magnetic 
resonance (MR) image of a silica particle and that of a GSS 
sample Where The GSS particle imparts a positive enhance-
ment in the T 1 weighted image and a negative enhancement 
for a T 2 weighted image according to an embodiment of the 
invention. 
FIGS. SA-B show transmission electron microscopic 
(TEM) images of Gd-doped GSS multimodal nanoparticles 
of about 100 nm (FIG. SA) and about 50 nm (FIG. SB) 
according to an embodiment of the invention. 
FIG. 6 shows a TEM image of Gd-doped GSS multimodal 
nanoparticles of about 225 nm according to an embodiment 
of the invention; 
FIG. 7A shows a high resolution TEM image where dark 
gold speckles are observed on the silica of a GSS multimodal 
nanoparticle and FIG. 7B shows a dark field TEM image of 
the GSS multimodal nanoparticle according to an embodi-
ment of the invention. 
FIG. 8 shows a high resolution TEM image where the 
lattice planes of the gold speckles deposited on silica ofa GSS 
multimodal nanoparticle according to an embodiment of the 
invention. 
FIG. 9 shows an EDS spectrum of Gd-doped GSS multi-
modal nanoparticles showing the presence of Si, 0, Au and 
Gd according to an embodiment of the invention. 
FIG. lOA shows A) T1-weighted (repetition time (TR)=l 1 
000 ms, echo time (TE)=4.2 ms), and FIG. lOB shows 
T 2 *TR =500 ms, TE=40 ms images of serial dilutions of Gd 
doped GSS nanoparticle (a) 0.24, (b) 0.12, (c) 0.06, (d) 0.03 
and ( e) 0.015 mM of Gd in 0.5% agarose and (f) 0.5% agarose 
(as control) according to an embodiment of the invention. 
15 FOV=2.8x2.74 cm, 2 avg, 1 mm slice; FIG. 17C spin echo 
(Msme) TR=276 ms, TE=5.5 ms, matrix=128x256, 
FOV=2.8x2.74 cm, 2 avg, 1 mm slice; and FIG. 17D spin 
echo (Msme) fat suppression, TR=276 ms, TE=5.5 ms, 
matrix=128x256, FOV=2.8x2.74 cm, 2 avg, 1 mm slice, 
20 according to an embodiment of the invention. 
FIG. 18 shows PAT images of a mouse before (left) and 
after (right) the injection with the multimodal nanoparticles 
where the red (appearing as a plurality of dark regions within 
a white region of the image) shows the contrast in the pres-
25 ence of the multimodal nanoparticles according to an 
embodiment of the invention. 
FIGS. 19A-B show a PAT image (FIG. 19A) of an animal 
model of a tumor region 3 hours post injection with multimo-
dal nanoparticles after subtracting the initial image, and an ex 
30 vivo fluorescence image (FIG. 19B) of the tumor section 
according to an embodiment of the invention. 
FIG. 20 is a plot of temperature rise in a solution containing 
10 mg/mL GSS multimodal nanoparticles on exposure to 
continuous illumination from a 785 nm laser with a 350 mA 
35 output according to an embodiment of the invention. 
FIGS. 21A-D show an A549 cell with GSS multimodal 
nanoparticles before laser exposure (FIG. 2 lA) and after laser 
exposure (FIG. 21B) for 100 s, which formed a bubble due to 
the heating and anA54 9 cell before laser exposure (FIG. 21 C) 
40 and after laser exposure (FIG. 21D) for 100 s without bubble 
formation according to an embodiment of the invention. 
FIGS. 22A-B show cells labeled with GSS multimodal 
nanoparticles along a path of laser illumination (FIG. 22A) 
and at a higher magnification (FIG. 22B) according to an 
45 embodiment of the invention. 
FIGS. llA-C show linear plots of Gd concentration vs. 
(FIG. llA) 1/T1 , (FIG. llB) 1/T2 , and (FIG. llC) 1/T2 * to 50 
determine ionic relaxivities R1 , R2 , and R2 * for Gd-doped 
GSS multimodal nanoparticles according to an embodiment 
FIG. 23 shows a photograph of a histological section of a 
tumor after thermal ablation with GSS multimodal nanopar-
ticles illuminated with 785 nm laser for 5 minutes according 
to an embodiment of the invention. 
FIG. 24 shows an Hand Estain of a tumor section indicat-
ing destruction of tumor cells upon illumination ofGSS mul-
timodal nanoparticles according to an embodiment of the 
of the invention. 
FIG. 12 shows PAT contrast for gold and GSS multimodal 
nanoparticles of similar size and concentration (8 µL of 10 55 
mg/mL) in a tissue-like phantom with background absorption 
coefficient µa=0.007 mm- 1 and reduced scattering coefficient 
µa'=0.5 mm- 1 according to an embodiment of the invention. 
FIGS. 13A-B show a PAT (FIG. 13A) and MRI T1 (FIG. 
13B) contrast from the same phantom using 1, 3 and 5 µL 60 
(particle concentration 10 mg/mL) of Gd-doped GSS multi-
modal nanoparticles with background coefficient µa=0.007 
mm- 1 according to an embodiment of the invention. 
FIG. 14 Panel I shows the position of J 774 microphage 
cells labeled with GSS multimodal nanoparticles marked as A 65 
and unlabeled cells marked as B in a phantom; Panel II shows 
the PAT image; Panel III is a T 1 -weighted spin-echo image 
invention. 
DETAILED DESCRIPTION OF THE INVENTION 
According to various embodiments, multimodal nanopar-
ticles have a plurality of agents chosen from fluorescent con-
trasting agents, MRI contrasting agents, an x-ray contrasting 
agents, and PAT contrasting agents.A single moiety can func-
tion as one on a plurality of contrast agents. Examples of 
contrast agents for luminescence (such as fluorescence, phos-
phorescence, and colorimetric) imaging include, but are not 
limited to, dyes, quantum dots, and phosphors. Examples of 
MRI imaging contrast agents include, but are not limited to, 
paramagnetic substances or substances containing particles 
exhibiting ferromagnetic, ferromagnetic or super paramag-
US 8,361,437 B2 
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netic behavior. Paramagnetic MRI contrast agents can be, for 
example, transition metal chelates and lanthanide chelates 
like Mn-EDTA (ethylene diamine tetraacetic acid) and Gd-
DTPA (diethylene triamine pentaacetic acid). 
6 
application as traceable hyperthermia agents. The multimo-
dal nanoparticles can be injected into an animal and actively/ 
passively targeted to a tumor site, exploiting the well known 
enhanced permeability and retention (EPR) effect, as illus-
trated in FIG. 2. The GSS nanoparticles can absorb light in the 
visible to Near Infrared (NIR) wavelength range where heat is 
generated as a result of their absorption. The heat generating 
ability makes them useful for therapeutic hyperthermia appli-
cations. The located tumors can be specifically targeted to 
10 heat and destroy the malignant cells that include the multi-
modal nanoparticles. 
IR absorbing dyes include indocyanine green, Cy-5 and 
others. Contrast agents for PAT work by selectively absorbing 
radiation in certain organs, or parts of organs, and efficiently 
converting that radiation into pressure waves or by scattering 
and diffusing the incipient light so that it more uniformly 
illuminates the target organs. The radiation may be electro-
magnetic radiation in the visible, infrared, microwave or 
other parts of the electromagnetic spectrum. Contrast agents 
for PAT include, but are not limited to, dyes, metal nanopar-
ticles, and metal nanoshells, and metal speckled nanopar-
ticles. Nanoshells can be composed of a dielectric core, usu- 15 
ally silica, surrounded by a discrete thin continuous metal 
shell, typically gold. Metal speckled nanoparticles can be 
composed of a dielectric core, usually silica, surrounded by 
an interpenetrated, molecularly-seeded, discontinuous gold 
film. Metal speckled nanoparticles have a non-discrete inter- 20 
face with the dielectric core establishing an interpenetrated 
gradient between the core and the outer discontinuous metal-
Materials and Methods 
Materials Tetraethylorthosilicate (TEOS), Triton X-100 
(TX-100 ), n-hexanol, 3-( aminopropy l)triethoxysilane 
(APTS), and cyclohexane were purchased from Aldrich 
Chemical Co. Inc. N-(Tri-methoxysilyl-propyl)ethyldiamin-
etriacetic acid disodium salt (TSPETE) ( 45% wt % solution 
in water) was purchased from Gelest Co., gold chloride, 
gadolinium acetate, and hydrazine hydrate were obtained 
from Acros Organics, and ammonium hydroxide (NH4 0H, 
28-30 wt%) was obtained from the Fisher Scientific Co. All 
other chemicals were of analytical reagent grade. Deionized 
lic film. These features result in alternative physical param-
eters that can be adjusted and modified to optimize particle 
performance for imaging and therapeutic applications. 
In one embodiment of the invention, multimodal nanopar-
ticle can include a core formed of a dielectric material such as 
Si02 . The core can include fluorescent dyes which can cover 
25 (DI) water (NANOpure, Barnstead) was used for the prepa-
ration of all solutions. 
Synthesis of Gd-Doped GSS Nanoparticles. The complete 
synthesis of the multimodal nanoparticles was done in one pot 
using reverse micelles. The water-in-oil (W/O) microemul-a desired spectrum range from visible to near IR. In other 
embodiments of the invention, the core can contain quantum 
dots and/or phosphors. 
In one of the embodiments, multimodal nanoparticle can 
30 sion was prepared by mixing TX-100 cyclohexane, n-hexanol 
(1:4.2:1 v/v), and appropriate water. n-Hexanol was used as a 
co-surfactant to the nonionic surfactant, TX-100. An amount 
of0.050 mL ofTEOS was added to the microemulsion and be doped with a (para) magnetic element, such as lanthanides, 
including Gd, Eu, Dy, and Tb, and/or transition metals includ-
ing Mn, Fe etc. These paramagnetic species, in addition to 35 
their magnetic influence and ability to generate contrast for 
MRI, can have a luminescence property. In certain embodi-
ments, these lanthanides function as fluorescent agent in the 
multimodal nanoparticle in addition to their function as the 
MRI contrast agent. The heavy atomic weight lanthanides 40 
and/or transition elements can function as an X-ray contrast 
agent in the multimodal nanoparticles. 
In one embodiment of the invention, the multimodal nano-
particle contain fluorescent species included on a silica core a 
paramagnetic element tethered to the particle and speckled 45 
with a metallic element, such as gold, silver, copper, or zinc. 
This interpenetrated, discontinuous metallic surface on the 
primarily dielectric core imparts photo acoustic contrast from 
the particle. The metallic element and a lanthanide/transition 
paramagnetic element provide enhancement to the x-ray con- 50 
trast. In one embodiment of the invention schematically 
depicted in FIG. 1, the metallic coating results in a speckled 
gold nanoparticle, with Gd paramagnetic species and Fluo-
rescein isothiocyanate FITC dye within the silica core. One of 
ordinary skill in the art will understand that FIG. 1 is exem- 55 
plary and that other contrast agents, geometries and coatings 
can be included. 
In embodiments of the invention, the nanoparticles can be 
from less than 50 nm to more than 350 nm in cross section. In 
one embodiment of the invention the nanoparticles can be 60 
from less than 50 nanometers to about 100 nm in cross sec-
tion. Generally, but not necessarily, the nanoparticles will be 
approximately spherical in shape; however, the shape can be 
that of any ovoid, rod, plate or irregular. 
In addition to the multimodal nanoparticles value as mu!- 65 
tifunctional contrast agents, in embodiments of the invention, 
the multimodal nanoparticles can be employed in therapeutic 
allowed to equilibrate for 30 min. The hydrolysis and poly-
merization ofTEOS was initiated by adding 0.05-0.200 L of 
NH4 0H. The overall W 0 (water to surfactant molar ratio) of 
NH4 0H was 10 after addition. The silica polymerization 
reaction ran for 24 hour, the surface of the silica nanoparticle 
was modified with the addition of0.025 mL ofTSPETE and 
0.050 mL ofTEOS. The resulting solution was stirred over-
night. Subsequently, 0.10 mL of0.1 M Gd(III) acetate solu-
tion was added and stirring for 4 hours. This was followed by 
addition of0.5 mL of0.25 M HAuCl4 , prepared in degassed 
water, and 1.1 M solution of reducing agent (hydrazine 
hydrate). The solution was stirred for about 12 hours. The 
progress of the reaction at each step was monitored by UV-vis 
absorption spectroscopy. The Gd-doped GSS nanoparticles 
were isolated from the microemulsion by adding 5 mL of200 
proof ethanol. The solution was stirred for a few minutes. This 
led to the complete breakdown of reverse micelles with the 
formation of two immiscible layers of aqueous ethanol and 
cyclohexane. The nanoparticles along with the surfactant 
molecules were accumulated in bottom ethanol layer. The top 
layer of cyclohexane was carefully removed, and the particles 
were centrifuged. The particles were washed three times with 
ethanol and five times with water in order to completely 
remove surfactant molecules. Each centrifugation step, dur-
ing washing was followed by vortexing and sonication to 
redisperse the pelleted particles. After complete removal of 
surfactant the particles were redispersed in N anopure water to 
obtain a concentration of about 2 mg/mL for further charac-
terization. 
Particle Size Measurements. The particle size and distri-
bution were measured by dynamic light scattering (DLS) 
using a Microtrac NANOTRAC and CPS disk centrifuge. The 
size and morphology of the particles were determined by 
transmission electron microscopy (TEM). TEM and energy-
US 8,361,437 B2 
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dispersive X-ray spectroscopy (EDS) spectra of the particles 
were done using JEOL 2010F transmission electron micro-
scope. 
Inductively Coupled Plasma Experiments. Inductively 
coupled plasma (ICP) measurements were performed using a 5 
Perkin-Elmer Plasma 3200 system equipped with two mono-
chromators covering the spectral range of 165-785 nm with a 
grated ruling of3600 lines/mm. Briefly, 0.050 g of the nano-
particle sample was digested using aqua regia solution. [Cau-
tion: Aqua regia digestion should be performed with care in a 10 
hood. Its reaction with GSS nanoparticles produces acrid and 
toxic fumes.] Au and Gd completely dissolved in the aqua 
regia, whereas the silica matrix settled at the bottom of the 
container as a white powder. After complete digestion, the 
solution was filtered to separate the silica particles as residue. 15 
The particles were washed three times with aqua regia solu-
tion and twice with nanopure water. The filtrate and the par-
ticles were all collected together and boiled to concentrate the 
volume to 15.0 mL. After instrument calibration was per-
formed for Au and Gd estimation, the filtrate was analyzed by 20 
ICP for quantitative estimation of Gd and Au. 
MR Phantom Preparation for Relaxometry Measurements. 
MRI measurements were recorded using a 4.7 T Bruker 
Avance MR camier. Particle phantom were prepared for MR 
relaxometry measurements by serially diluting a 10 mg/mL 25 
stock solution of Gd-doped GSS nanoparticles with doubly 
distilled H2 0 and a 1 % agarose solution (Ultra-Pure agarose, 
Invitrogen, Carlsbad, Calif.) yielding a total concentration of 
0.5% agarose. The resulting nanoparticle concentrations of 5, 
2.5, 1.25, 0.625, and 0.3125 mg/mL were then injected into 30 
100 µl capillary tubes (Curtin-Matheson Scientific, 181 
Broomall, Pa.) and allowed to solidify on ice, thereby elimi-
nating sedimentation during relaxometry measurements. The 
comparison of MR response between Gd-doped GSS nano-
particles and silica nanoparticles (without any gold or Gd) 35 
was performed similarly by diluting 10 mg/mL nanoparticles 
8 
rates (1/T1 2 (s-
1
)). Finally, R1 2 values were plotted against 
the concei:{tration of Gd on the nanoparticle and r1 and r2 
(mM- 1 s- 1) relaxivities were obtained as the slope of the 
resulting linear plot. 
T 2 * relaxometry measurements were acquired by T 2 *-
weighted FLASH gradient echo scan sequences. TRs were 
kept constant at 500 ms with varying TEs of 4, 8, 12, 16, 20, 
40, 60, and 100 ms, FOV=2.8x2.8 cm2 , matrix size=256x 
256, two signal 219 averages, spectral width=60 kHz, and 1 
mm slice thickness. Image J software (NIH) with an MR 
analysis calculator plug-in was used to quantify T 2 *values by 
stacking the individual FLASH sequences with varying TEs 
and creating a T 2 *map. RO Is for each cell sample were then 
drawn to contain the entire cross section of each of the 
samples, and values were then plotted as R2 * (or the inverse of 
T2 * (1/T2 *, (s-
1
))), against the concentration of Gd in the 
sample (Excel, Microsoft Inc.). R2 * relaxivity (mM-
1 s) was 
later obtained as the slope of the resulting linear plot. Data are 
presented as the mean±SD of measurements. 
PAT Instrumentation. A mechanical scanning photoacous-
tic system with single acoustic transducer to collect the 
acoustic signals was utilized. A pulsed Nd:YAG laser (Altos, 
Bozeman, Mont.) working at 532 nm with 4 ns pulse duration, 
10 Hz repetition rate and 3 60 ml maximum pulse power acted 
as light source. The diameter of laser beam was expanded to 
30 mm by a lens. An immersion acoustic transducer with 1 
MHz nominal frequency (Valpey Fisher, Hopkinton, Mass.) 
was driven by a motorized rotator to receive acoustic signals 
and 360° for phantom cases at an interval of 3°, and thus a 
total of 120 measurements were performed for one planar 
scanning, respectively. The scamiing plane could be adjusted 
along the z-axis by mounting the rotator and the transducer on 
a platform driven by a linear stage. The acoustic transducer 
was immersed into the water tank while the phantom was 
placed at the center of the tank where it was illuminated by the 
laser. The complex wave field signal was amplified by a 
pulser/receiver (GE Panametrics, Waltham, Mass.) and then 
was acquired by a high-speed PCI data acquisition board. PAT 
images were reconstructed by a reconstruction algorithm that 
in 1 % agarose solution, confirming that the silica matrix alone 
does not exhibit significant photo acoustic and MR contrast. 
FIG. 3 and FIG. 4 demonstrate that silica does not exhibit 
significant photo acoustic or MR contrast respectively. Con-
trol phantoms containing just 0.5% 187 and 1 % agarose were 
simultaneously imaged to determine effect of agarose on 
relaxation times. Right before imaging, all samples were 
placed together inside a water-filled FACS tube (BD Falcon, 
Franklin Lakes, N.J.) to avoid susceptibility artifacts from the 
surrounding air. 
40 is based on the finite element solution to the photoacoustic 
wave equation in the frequency domain, which can provide 
stable inverse solutions. Phantoms for imaging were con-
structed using intralipid, India ink, distilled water, and 2% 
agar powder as described above. The diameters of all phan-
45 toms used in this study were 25 mm. The absorption and 
reduced scattering coefficients (optical properties) of these 
phantoms were 0.007 and 0.5 255 mm- 1 , respectively. Nano-
particles were embedded in the phantom 256 at a depth of 2 
MR Relaxometry for Gd-Doped GSS Nanoparticles. All 
relaxometry data was acquired at a 4.7 T horizontal bore 
magnet with Paravision software (PV3.02; Bruker Medical). 
For measuring T 1 relaxation times, axial spin-echo (SE) scan 50 
sequences were obtained with TE=4.5 ms, matrix size) 128x 
128, FOV=2.8 197x2.8 cm2 , spectral width=180 kHz, one 
average, 1 mm slice thickness, and varying TR values of 11, 
mm for imaging. 
Macrophage Labeling and Phantom Preparation for MRI 
and PAT. Mouse monocyte/macrophage 1774 cells were 
defrosted, resuspended in DMEM complete, consisting of 
Dulbecco's modified agle's medium (DMEM) (GIBCO, 
Grand Island, N.Y.) supplemented with 10% fetal bovine 6, 3, 1.5, 0.75, 0.5, 0.25, 0.125, 0.075, 0.05, 0.025, and 0.015 
s. For T 2 relaxation measurements, axial T 2 -weighted single-
slice multiecho images were obtained with TR=l 1 s, TE=5 
ms, llTE=5 ms (60 echoes), matrix size=128x128, 
FOV=2.8x2.8 cm2 , spectral width=lOOkHz, two signal aver-
ages, and a 1 mm slice thickness. Analysis ofT 1 and T 2 values 
was performed using Paravision 3 .02 software where T 1 and 
T 2 maps were calculated assuming a monoexponential signal 
decay and by using a nonlinear function, least-squares curve 
fitting on the relationship between changes in mean signal 
intensity within a region of interest (ROT) to TR and TE. T 1 
and T2 relaxation times(s) for the Gd-doped GSS nanopar-
ticles in 0.5% agarose were then derived by ROI measure-
ments of the test samples converted into R1 and R2 relaxation 
55 serum (Summit Biotechnology, Ft. Collins, Colo.), 1 % 
glutamax (GIBCO), 1 % penicillin/streptomycin (GIBCO), 
and incubated at a density of 5xl05 cells/mL in 100 mm 
culture dishes at 37° C. and 5% C02. Media was replaced 24 
h after plating, and the cells were allowed to attach and grow 
60 to confluency (usually within 2-3 days). Old media was 
replaced with fresh before the cells were harvested and 
washed twice by spinning them down at 1100 rpm for 5 min 
using a Sorvall RT7 plus ultracentrifuge and resuspending in 
fresh DMEM complete media. Cells were subsequently 
65 replaced at a density of 2x 105 and again allowed to attach and 
grow to confluency. Cells were passaged for 3-4 times before 
the start of the labeling experiment. During labeling, 1xl06 
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freshly split 1774 cells/mL DMEM complete were incubated 
overnight with 100 µg/mL of Gd-doped GSS nanoparticles in 
a six-well tissue culture dish. The next day label-containing 
media was aspirated off and replaced by fresh media before 
labeled and unlabeled control cells were scraped up, washed 5 
twice in ice-cold Dulbecco's phosphate-buffered saline 
(DPBS) (GIBCO, Grand Island, N.Y.), counted, and resus-
pended at a density of 3.33xl07 cells/mL each in DPBS 
(2xl 06 cells in 60 µL DPBS). Cells were kept on ice until the 
time of imaging when 20 µl of cell suspension was then 10 
injected in the phantom. The same phantom was used for MRI 
and PAT experiments in succession. 
MRI Measurements on 177 4 Cells Labeled with Gd-Doped 
GSS Nanoparticles. The sample phantom containing GSS-
labeled 1774 and control cells was placed inside a solenoid 15 
coil and imaged at 4.7 T magnetic field strength with Paravi-
sion software (PV3.02; 288 Bruker Medical). T1- and 
T 2 -weighted SE scan sequences were used to detect Gd on the 
nanoparticles inside the cells. For generating T 1 -weighted 
images a multislice multiecho (MSME) pulse sequence was 20 
used with TR=500 ms, TE=5 ms, matrix size=256x256, 
FOV=3x3 cm2 , spectral width=! 00 kHz, two signal averages, 
and a 1 mm slice thickness. T 2 -weighted images was acquired 
either by using a MSME pulse sequence with TR=500 ms, 
TE=lOO ms, matrix size 256x256, FOY 3x3 cm2 , spectral 25 
width=lOOkHz, two signal averages, anda 1 mm slice thick-
ness or by using a rapid acquisition with relaxation enhance-
ment (RARE) pulse sequence with TR= 1000 ms, TE= 12 ms, 
matrix size=256x256, FOV=3x3 cm2 , spectral width=60 
kHz, four signal averages, RARE factor=8, and a 1 mm slice 30 
thickness. 
10 
the deposition of the gold nanodomains. The gold nan-
odomains are discontinuous, randomly deposited, sometimes 
templated, and irregular gold nanoclusters can form within 
and on the surface of the silica core. High-resolution TEM 
(HR-TEM) micrographs of about 100 nm Gd-doped. GSS 
nanoparticles (prepared at WO=lO) demonstrate speckled 
surface deposits of gold, as seen in areas of darker contrast on 
the silica surface in FIG. 7(a) and as areas oflighter contrast 
in the dark-field TEM shown in FIG. 7(b). Note that Gd 
doping also contributes to the background as a darker and 
lighter haze in FIG. 7(a) and FIG. 7(b), respectively. The 
HRTEM micrograph of FIG. 8 shows scattered deposition of 
gold nanoparticles ranging from less than 1 to 5 nm, with 
varying crystallinity, on the silica surface. These random and 
irregular clustered deposits include templated deposits. The 
mesopores make this class of particles distinct and accounts 
for their unique optical properties such as efficient photother-
mal properties. Since these particles were also doped with Gd 
ions, a paramagnetic species that affects the longitudinal 
relaxation rate of water, they provided MRI contrast. 
The elemental composition of the Gd-doped GSS nanopar-
ticles particles was determined using EDS and lCP tech-
niques. An EDS spectrum is shown in FIG. 9 with spectral 
counts corresponding to Si, 0, Au, Gd, and the overall spec-
trum for the nanoparticle, respectively. The elemental com-
position as determined by ICP gave average number of atoms 
of Au and Gd to be about 426 200 and about 34 000 per 
nanoparticle, respectively. Theoretical calculations showed 
that about 72 times more number of gold atoms would be 
present in a single gold nanoparticle of similar dimension. 
The Gd-doped GSS nanoparticles generated MR contrast 
on both T 1 and T 2 proton relaxation time weighted sequences, 
as are shown in FIG. lO(a) and FIG. lO(b). Quantitatively, 
MR contrast is evaluated by the relaxivity of the nanoparticle. 
In one embodiments of the invention, gold-silica hybrid 
material termed gold speckled silica (GSS) nanoparticles are 
provided. These MRI-PAT-active multimodal nanoparticles 
have a surface layer composed of discontinuous, irregular 
gold nanodomains of varying crystallinity that are incorpo-
rated within the pores and on the exterior of the supporting 
silica matrix. The multitude of dielectric-metal interfaces 
created by this method gives rise to unique photothermal 
properties that enable the use of these materials as contrast 
agents in PAT. The multimodal GSS nanoparticles possess 
high relaxivity for MRI and at the same time produce a strong 
PAT contrast. 
35 The relaxivity (R,, i=l, 2) is defined as the gradient of the 
linear plot ofrelaxation rates (l!T,, i=l, 2) versus Gd concen-
tration [Gd], i.e., l/T,=l/T
0
+R,[Gd], where Ti is the relax-
ation time for a contrast agent solution concentration [Gd] 
and T 
0 
is the relaxation time in the absence of a contrast agent. 
In one embodiment, the GSS nanoparticles are formed by 
first forming Gd-doped silica nanoparticles by co-condensa-
tion of TEOS and a silane reagent that strongly chelates 
polyvalent metal ions (TSPETE) in the water core of the 
TX-100/n-hexanol/water W /0 microemulsion. Incorporation 
40 From the data shown in FIG. 11, the relaxivities R1 , R2 , and 
R2 * are determined to be 13, 110, and 173mM-1 s- 1,respec-
tively. Gd-GSS exhibit much higher relaxivity values than 
commercially available contrast agents under the same mag-
netic strength of 4.7 T. In MRI, it is well-established that the 
45 Gd-generated MR contrast relies on the relaxation process of 
the water molecules in association with the Gd ion and those 
of chloroauric acid followed by its reduction was then carried 
out within the surface layer of the silica nanoparticles. By 50 
manipulating W 0 of the microemulsions and the reactant con-
centrations, we were able to tune Gd-doped GSS nanoparticle 
size from less than 50 to 200 nm. FIGS. S(a) and S(b) show 
representative TEM micrographs for two different samples 
prepared at W0 10 and 14, depicting mean particle size of 55 
about 100 (±10) and 55 (±5) nm, respectively. GSS nanopar-
ticles up to 200 nm and larger were synthesized at W 0 5 using 
the same microemulsion system. FIG. 6 shows large sized 
(>200 nm) GSS nanoparticles prepared in the Tx-100/cyclo-
hexane/water system at W0=5, following the conditions as 60 
described above. 
exchanged in the surrounding environment. For an efficient 
relaxation process, rapid water exchange between bound (or 
inner coordination water) with the bulk water and slow tum-
bling play an important role. The Gd-doped GSS nanopar-
ticles address both these factors. First, the presence of the 
discontinuous GSS surface allows sufficient bulk water 
exchange with the Gd ions enabling MR tracking ability. In 
comparison, a continuous gold shell over the silica core could 
limit the extent of water exchange inhibiting T 1 contrast. 
Second, tumbling rates are another important factor for pro-
ducing an effective MRI contrast is also reduced in the Gd 
doped GSS particles through the rigid binding of Gd to the 
nanoparticle surface. Because the tumbling rates are mass 
dependent, nanoparticles are much slower than free Gd che-
lates and thus produce an enhanced relaxation. One of the 
major limitations of current molecular chelates used as MR 
contrast agent is their low sensitivity; this requires the use of 
higher dosages and results in poor targetability. Both of these 
The particle sizes were confirmed using DLS and disk 
centrifuge techniques. In one embodiment of the invention, 
by incubating Gd-doped silica nanoparticle within the aque-
ous core of the microemulsion with chloroauric acid, gold 
ions permeate further into the mesoporous silica matrix. 
Upon reduction, a unique gold-speckled surface results due to 
65 problems are addressed by embodiments of the invention. 
Approximately, 34 000 ions of Gd are captured per nanopar-
ticle with an average size of 100 nm, which is higher than the 
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number of Gd ions previously reported in other nanoparticles 
such as synthetic polymers (6-70 ions) and in dendrimers 
(between 5 and 1331 ions, strongly dependent on particle 
size) and comparable to perfluorocarbon nanoparticles (90 
000 Gd ions in 250 nm diameter particle). The ability of 
Gd-GSS nanoparticles to generate photoacoustic contrast 
was confirmed by placing the particles in an agar phantom 
containing India ink and intralipid to simulate tissue-like 
absorption and scattering. FIG. 12 shows the comparison of 
PAT contrast from GSS nanoparticles and compares it to that 10 
of similar size and concentration of gold nanoparticles. The 
dark red region in the area ofthenanoparticles, with respect to 
the blue background, demonstrates that a strong PAT contrast 
is observed from the particles. As shown in FIG. 12, the GSS 
nanoparticles generated a strongerphotoacoustic signal when 15 
compared the GSS nanoparticles, in spite of the presence of 
-72-fold less gold atoms, demonstrates them as a better PAT 
contrast agent. Control experiments were also performed 
using silica nanoparticles (without Au or Gd) which illus-
trated that the bare silica nanoparticles do not have a signifi- 20 
cant PAT contrast. Because the PAT originates from the opti-
cal absorption of the illuminating laser wavelength, the GSS 
particles also hold therapeutic potential for the thermal abla-
tion of tumors. Hence, the particles described here hold both 
multimodal imaging as well as therapeutic capabilities. To 25 
evaluate the bimodal character of the GSS nanoparticles, 
simultaneous MR and photoacoustic evaluation was carried 
out. To achieve this, the GSS particles were placed in tissue-
like phantom. The phantom was imaged for PAT and MR in 
succession, and the results are shown in FIGS. 13( a) and ( b ), 30 
respectively. An increase in the MR and PAT signal intensity 
is observed with increasing particulate concentration. In vitro 
studies were carried out with the GSS nanoparticles to assess 
the functional ability of the particles in the cellular environ-
ment. The uptake of the GSS nanoparticles by 1774 macroph- 35 
ages was carried out as described above. The cells were 
placed in tissue-like phantom and imaged by PAT and MRI in 
succession. FIG. 14 shows the phantom design with the 
sample placement and the MR and PAT images obtained with 
the same phantom. It is observed that the cells labeled with the 40 
GSS nanoparticles produce a strong PAT contrast as com-
pared to the background. The MRI image of the same phan-
tom shows the ability to generate the T 1 and T 2 contrast. The 
in vitro experiments demonstrated the capability of the GSS 
nanoparticles to generate an efficient PAT and MR contrast in 45 
contrast in living cells, showing potential use of GSS nano-
particles as in vivo cell tracker. 
Multimodal nanoparticles with silica core according to an 
embodiment of the invention can be made fluorescent by 
coupling Fluorescein isothiocyanate (FITC) can be prepared 50 
in the manner described above for the GSS particles. Alan-
thanide metal was attached to the surface of the core by 
co-condensing a silane ligand on the silica surface. The par-
ticle surface was then coated with gold within the water core 
12 
determined from the slope of the relaxation graphs obtained 
by serial dilutions of the sample normalized to Gd. The T 1 
contrast generated from the serial dilutions of the nanopar-
ticles at 5 mg/mL, 2.5 mg/mL, 1.25 mg/mL, 0.625 mg/mL, 
0.3125 mg/mL suspended in 0.5% agarosewitha TR ofl 1000 
ms and TE of 4.5 ms was clearly enhanced relative to 1 % and 
0.5% agarose solution controls. 
PAT contrast from the multimodal nanoparticles was deter-
mined where pulsed light with incident fluence ofl 0 mJ/cm2 , 
well below the safety standard from a Nd: YAG laser (wave-
length: 532 nm, pulse duration: 4 ns) was coupled into the 
phantom via an optical subsystem and generated acoustic 
pressure wave. A wide-bandwidth, 1 MHz transducer was 
used to receive the acoustic signals. The transducer and the 
phantom were immersed in a water tank. A rotary stage 
rotated the receiver relative to the center of the tank. One set 
of data was taken at 120 positions when the receiver was 
scanned circularly over 360°. The PAT picture was generated 
by processing the data collected using standard algorithms. 
The ability to generate x-ray contrast by the multimodal 
particles was demonstrated by suspending about 20 mg/ml of 
nanoparticles in nanopure water, using nanopure water as 
control. FIG. 16 shows the strong x-ray contrast generated 
from the iron doped multimodal nanoparticles. 
In vivo testing using the exemplary multimodal nanopar-
ticles for MRI and PAT was then performed. Two (2) million 
1774 cells labeled with the multimodal nanoparticles were 
injected into the right leg of the mouse while unlabeled cells 
were injected into the left leg. The animal was MR imaged on 
4.7 T MRI scanner immediately following injection. The in 
vivo MR images shown in FIG. 17 demonstrate the ability of 
the particles to generate sufficient MR contrast in live ani-
mals. 
An MCF7 tumor was grown in the mouse abdomen. PAT 
images were taken before and after the injection of multimo-
dal nanoparticles injected in the MCF7 tumor. FIG. lS(a) and 
FIG. 18(b) show the PAT images obtained under similar 
experimental conditions for a tumor before and after injection 
with the multimodal nanoparticles. It is shown clearly that the 
particles can be used to image the tumor, in vivo conditions. 
GSS nanoparticles doped with FITC dye were prepared in 
the microemulsion in the manner described above. GSS nano-
particles were pegylated by reacting with Peg-thiol using 
standard protocols. 100 µl (particle concentration 10 mg/mL) 
pegylated nanoparticles were injected in the tail vein of the 
animal model (breast cancer). The tumor region in the animal 
was monitored by PAT before and after the injection of nano-
particles at 3 and 5 hour interval. The nanoparticles injected 
into the animal model were passively targeted to the tumor 
site by the well known Enhanced permeability and retention 
(EPR) effect. 
Results from a PAT experiment and ex-vivo fluorescence 
studies are shown in FIG. 19. FIG. 19(a) shows a representa-
tive PAT image from subtraction ofinitial PAT image (prior to 
injection of nanoparticles) from the PAT image obtained 3 
hour post injection. The deep red regions (appearing as a 
plurality of dark regions within a white region of the image) 
result from the localization of the GSS particles around the 
tumor. To confirm the findings from PAT imaging, tumor 
of the microemulsion. This led to the gold speckled surface 55 
coated multimodal nanoparticles shown in FIGS. 15(a) and 
15(b) as SEM and TEM images, respectively, of the multi-
modal nanoparticles. Using Dynamic Light Scattering, the 
size of the multimodal nanoparticles was determined to be 
about 50 nm to about 100 nm. 60 sections from the animal model were checked for fluores-
cence after sacrificing the animal. FIG. 19(b) shows the fluo-
rescence image of the tumor tissue section. The green fluo-
rescence (white in the grayscale reproduction of the image) 
emanates from the presence of fluorescent-GSS nanoparticles 
The multimodal nanoparticles generated contrast in MR 
images, where glass micropipettes (250 µL in volume) were 
filled with about 200 µL of serial dilutions of multimodal 
particles and placed in a single-tuned solenoid coil (200 
MHz) with an inner diameter of 1 cm, and data were recorded 
at room temperature using a 4.7 T (200 MHz) Bruker Avance 
MR scanner.Tu T 2 , and T 2 * relaxivities for the particles were 
65 (FITC) in the tumor vasculature and the blue fluorescence 
(gray in the grayscale reproduction of the image) is seen from 
the nuclear stain DAPI. Hence this confirms that GSS nano-
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particles falling in the path of the laser are killed selectively, 
as shown as a dark vertical line at the center of FIG. 22(a) 
which is magnified in FIG. 22(b). 
The ability to generate heat using with NIR laser allows 
targeting deep tumors due to higher penetration in this region. 
To demonstrate the feasibility of using GSS nanoparticle for 
tumor hyperthermia, GSS nanoparticles were injected 
directly into the tumor of animal model. The tumor region 
was then illuminated with 785 nm laser (0.350 mA output) for 
particles can be tracked non-invasively using PAT in vivo and 
can be confirmed by a second mode (fluorescent) in the mul-
timodal nanoparticles. The GSS nanoparticles have an 
absorption maximum at about 530 nm and, in general, 
strongly absorbs in the region of 450 to 850 nm. This absorp-
tion is remarkably different from the starting materials i.e. 
silica and gold chloride. The light absorbing character of GSS 
nanoparticles in the visible to Near Infrared (NIR) wave-
length range makes the particles generate heat as a result of 
such absorption making them useful for therapeutic hyper-
thermia applications. FIG. 20 shows the rise in temperature of 
solution containing GSS nanoparticles (10 mg/mL) when 
illuminated with 785 nm NIR laser. The laser output was 
maintained at 350 mA during the experiment. GSS nanopar-
ticles showed a rise of -15° C. in 5 minutes on continuous 
illumination with NIR laser as compared to about 1 ° C. rise 
observed with nano pure water. For hyperthermia, an increase 
10 duration of 5 minutes. The effect on the tumor was checked by 
performing the histological analysis of the tumor after sacri-
ficing the mice. FIG. 23 shows the image of the tumor post 
ablation experiment. It is evident from the figure that the GSS 
nanoparticles caused significant damage to the tumor tissue 
15 from theheat generated due to exposure to NIRlight. FIG. 24 
shows the Hand Estain of the tumor section. 
of about 8-10° C. over the normal physiological temperature 
is known to cause disruption of the cellular metabolism lead-
ing to eventual death. From the above results it is apparent that 
GSS nanoparticles are capable of sufficiently elevating the 
temperature to kill tumor cells. 
It should be understood that the examples and embodi-
ments described herein are for illustrative purposes only and 
that various modifications or changes in light thereof will be 
20 suggested to persons skilled in the art and are to be included 
Lung A549 cancer cells were dosed with GSS nanopar-
ticles in various combinations of time and concentration; 18 
hrs incubation for 5 and 10 µg/ml; and 24 hrs incubation for 25 
20 µg/ml. Prior to illuminating the cells with a 785 nm laser 
the media was removed and the cells were rinsed with HBSS 
(Hanks Buffered Saline Solution) twice and fresh growth 
media was added. FIG. 21 shows the representative images of 
cells before and after exposure to laser. From FIG. 2l(c) and 30 
FIG. 21(d), before and after irradiation, it is clearly obvious 
thatA549 cells labeled with GSS nanoparticles undergo ther-
mally induced cell death when exposed to laser light. The 
process of laser illumination on GSS labeled cells and the 
effect of increase in temperature on cellular components has 35 
been studied by Raman spectroscopy. The overall process of 
cell death has been found to be necrotic. In this study a Raman 
technique as a tool to investigate effect of rise in temperature 
on the cell components. 
In another experiment the effectiveness of the particles to 40 
cause possible collateral damage on surrounding cells (those 
not exposed to laser) was studied. The labeled cells were 
illuminated with Laser of (20 by 40 micron spot size) at an 
estimated the speed to 2.5 mm/s. After the laser scanning was 
finished, 200 µl of 0.4% Trypan Blue solution in phosphate 45 
buffer was added to the cells. The plate was incubated for 15 
min in order for the Trypan Blue to selectively penetrate the 
membrane and color the dead cells. Images were taken with 
Olympus BX60 with an attached SPOT Insight Digital Cam-
era, as shown in FIG. 22. The cells labeled with GSS nano-
within the spirit and purview of this application. 
We claim: 
1. A multimodal nanoparticle comprising: 
a dielectric core comprising at least one oxide; 
a metal deposition on said core, wherein said metal depo-
sition is speckled; and 
a plurality of at least one moiety that exhibits fluorescence, 
magnetic or paramagnetic properties, or any combina-
tion thereof, wherein saidmultimodal nanoparticle com-
prises a contrast agent for photo acoustic tomography 
(PAT) imaging and x-ray imaging, and at least one of 
luminescence imaging moiety and/or magnetic reso-
nance (MR) imaging moiety, and wherein said metal 
deposition and said dielectric core have an interface with 
interpenetrated gradient. 
2. The nanoparticle of claim 1, wherein said luminescence 
imaging moiety comprises at least one of a dye, a quantum 
dot, and a phosphor. 
3. The nanoparticle of claim 1, wherein the MR imaging 
moiety comprises at least one lanthanide or transition metal. 
4. The nanoparticle of claim 1, wherein the oxide com-
prises silicon dioxide. 
5. The nanoparticle of claim 1, wherein the metal deposi-
tion comprises gold. 
6. The nanoparticle of claim 1, wherein saidnanoparticle is 
further surface modified with at least one biomolecule or 
surface functional group for specific targeting of a tumor cell 
or other biological tissue. 
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Column 7, 
Line 24, "MR canner" should read --MR scanner--. 
Line 51, "maxtrix size) 128" should read --matrix size 128--. 
Column 8, 
Line 53, "modified agle's medium" should read --modified eagle medium--. 
Column 10, 
Line 22, "EDS and JCP" should read --EDS and ICP--. 
Column 12, 
Line 48, "at 3 and 5" should read --at 1, 3 and 5--. 
Column 13, 
Line 38, "technique as a tool to investigate" should read --technique was used as a tool to 
investigate--. 
Line 44, "estimated the speed to" should read --estimated speed of--. 
Column 14, 
Line 4, "using with NIR laser" should read --using an NIR laser--. 
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